{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epstein-Barr+Virus&page=2", "query": { "condition": "Epstein-Barr Virus", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epstein-Barr+Virus&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-27T11:55:50.055Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00392834", "title": "Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "liposomal cytarabine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 34, "start_date": "2006-09", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-06-27T11:55:50.055Z", "location_count": 13, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00392834" }, { "nct_id": "NCT00248547", "title": "Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "aprepitant", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "ondansetron", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-05", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-06-27T11:55:50.055Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00248547" }, { "nct_id": "NCT04544592", "title": "UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia", "B-cell Non Hodgkin Lymphoma" ], "interventions": [ { "name": "CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "31 Days", "maximum_age": "30 Years", "sex": "ALL", "summary": "31 Days to 30 Years" }, "enrollment_count": 45, "start_date": "2021-03-10", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-06-27T11:55:50.055Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04544592" }, { "nct_id": "NCT04546399", "title": "A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Down Syndrome", "Recurrent B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Asparaginase Erwinia chrysanthemi", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Hydrocortisone Sodium Succinate", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 461, "start_date": "2020-12-17", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-06-27T11:55:50.055Z", "location_count": 209, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 150 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04546399" }, { "nct_id": "NCT05683834", "title": "Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epstein-Barr Virus Infection", "Infectious Mononucleosis", "Herpesvirus" ], "interventions": [ { "name": "Matrix-M1 Adjuvant", "type": "DRUG" }, { "name": "EBV gp350-Ferritin Vaccine", "type": "DRUG" }, { "name": "Placebo Comparator", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "18 Years to 25 Years" }, "enrollment_count": 25, "start_date": "2023-09-22", "completion_date": "2026-04-20", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-06-27T11:55:50.055Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05683834" }, { "nct_id": "NCT03394365", "title": "A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)", "Solid Organ Transplant Complications", "Lymphoproliferative Disorders", "Allogeneic Hematopoietic Cell Transplant", "Stem Cell Transplant Complications" ], "interventions": [ { "name": "tabelecleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pierre Fabre Medicament", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 115, "start_date": "2017-12-29", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-27T11:55:50.055Z", "location_count": 40, "location_summary": "Duarte, California • La Jolla, California • Loma Linda, California + 28 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03394365" }, { "nct_id": "NCT00309907", "title": "Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Disseminated Neuroblastoma", "Juvenile Myelomonocytic Leukemia", "Previously Treated Childhood Rhabdomyosarcoma", "Previously Treated Myelodysplastic Syndromes", "Pulmonary Complications", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "etanercept", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 39, "start_date": "2006-04", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2017-09-29", "last_synced_at": "2026-06-27T11:55:50.055Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Arcadia", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309907" }, { "nct_id": "NCT01948180", "title": "Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Extranodal NK-T-Cell", "EBV" ], "interventions": [ { "name": "baltaleucel-T", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cell Medica Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2014-09", "completion_date": "2018-09-07", "has_results": false, "last_update_posted_date": "2019-03-13", "last_synced_at": "2026-06-27T11:55:50.055Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • Columbus, Ohio + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01948180" }, { "nct_id": "NCT01786135", "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Burkitt Lymphoma", "Lymphoma, Follicular", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Mantle-Cell", "Precursor B-cell Lymphoblastic Leukemia-Lymphoma" ], "interventions": [ { "name": "SGN-CD19A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 64, "start_date": "2013-02", "completion_date": "2017-02-16", "has_results": false, "last_update_posted_date": "2017-10-19", "last_synced_at": "2026-06-27T11:55:50.055Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01786135" }, { "nct_id": "NCT00014482", "title": "Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety Disorder", "Chronic Myeloproliferative Disorders", "Depression", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Pain" ], "interventions": [ { "name": "pain therapy", "type": "PROCEDURE" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-12", "completion_date": "2003-03", "has_results": false, "last_update_posted_date": "2013-06-18", "last_synced_at": "2026-06-27T11:55:50.055Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014482" } ] }